Skip to content

Booksellers & Trade Customers: Sign up for online bulk buying at trade.atlanticbooks.com for wholesale discounts

Booksellers: Create Account on our B2B Portal for wholesale discounts

Dose-Finding Designs for Early-Phase Cancer Clinical Trials: A Brief Guidebook to Theory and Practice

by Takashi Daimon
Save 35% Save 35%
Current price ₹4,407.00
Original price ₹6,779.00
Original price ₹6,779.00
Original price ₹6,779.00
(-35%)
₹4,407.00
Current price ₹4,407.00

Imported Edition - Ships in 12-14 Days

Free Shipping in India on orders above Rs. 500

Request Bulk Quantity Quote
+91
Book cover type: Paperback
  • ISBN13: 9784431555841
  • Binding: Paperback
  • Subject: N/A
  • Publisher: Springer
  • Publisher Imprint: Springer
  • Publication Date:
  • Pages: 133
  • Original Price: EUR 59.99
  • Language: English
  • Edition: 2019
  • Item Weight: 240 grams
  • BISAC Subject(s): Biostatistics, Probability & Statistics / General, and Life Sciences / General

This book provides a comprehensive introduction to statistical methods for designing early phase dose-finding clinical trials. It will serve as a textbook or handbook for graduate students and practitioners in biostatistics and clinical investigators who are involved in designing, conducting, monitoring, and analyzing dose-finding trials. The book will also provide an overview of advanced topics and discussions in this field for the benefit of researchers in biostatistics and statistical science. Beginning with backgrounds and fundamental notions on dose finding in early phase clinical trials, the book then provides traditional and recent dose-finding designs of phase I trials for, e.g., cytotoxic agents in oncology, to evaluate toxicity outcome. Included are rule-based and model-based designs, such as 3 + 3 designs, accelerated titration designs, toxicity probability interval designs, continual reassessment method and related designs, and escalation overdose control designs. This bookalso covers more complex and updated dose-finding designs of phase I-II and I/II trials for cytotoxic agents, and cytostatic agents, focusing on both toxicity and efficacy outcomes, such as designs with covariates and drug combinations, maximum tolerated dose-schedule finding designs, and so on.

Takashi Daimon, Department of Biostatistics, Hyogo College of MedicineAkihiro Hirakawa, Center for Advanced Medicine and Clinical Research, Nagoya University Graduate School of MedicineShigeyuki Matsui, Department of Biostatistics, Nagoya University Graduate School of Medicine

Trusted for over 49 years

Family Owned Company

Secure Payment

All Major Credit Cards/Debit Cards/UPI & More Accepted

New & Authentic Products

India's Largest Distributor

Need Support?

Whatsapp Us